drugset / Trial / NCT07182305

Treatment Trial of Alveolar Echinococcosis

NCT07182305

RandomizedParallel-groupSingle-blindTreatment

Summary

A new focus of subjects with lesions of alveolar echinococcosis caused by Echinococcus multilocularis has been found south of Gulcha in Osh province in Kyrgyzstan by an ultrasound surveillance. Prevalence of infections is approximately 6%. Most lesions are small. Current scientific evidence suggests that in the absence of treatment, alveolar echinococcosis has a case fatality rate approaching 100% within 10-15 years of infection. Albendazole is known to be effective as a parasitostatic treatment to prolong the life of subjects with this disease, possibly up to normal life expectancy with prolonged treatment. The trial will be a case control study to evaluate the treatment of subjects with early stage alveolar echinococcosis and the progression of disease.

Timeline

Start
2017-05-01
Primary completion
2021-04-30
Completion
2023-07-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Albendazole Small molecule 400 mg